[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353717-105":59,"doc-detail-353717-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","new-genomic-and-proteomic-biomarker-discovery-in-cancer-revolutionizing-diagnosis-and-prognostication","New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication","","Cancer remains a major global health challenge with substantial morbidity and mortality worldwide. Advances in genomic and proteomic biomarker discovery have transformed cancer diagnosis, prognosis, and treatment selection. Progress from early serological markers such as CEA and PSA to multi-omics approaches enabled by NGS, mass spectrometry, and bioinformatics has driven personalized medicine and targeted therapy. The review covers liquid biopsies, AI, integrative multi-omics analytics, differing adoption across high-income versus LMIC settings, and key barriers such as heterogeneity, standardization, cost, and regulation, while highlighting innovations that support more equitable precision oncology.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-genomic-and-proteomic-biomarker-discovery-in-cancer-revolutionizing-diagnosis-and-prognostication/353717/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-genomic-and-proteomic-biomarker-discovery-in-cancer-revolutionizing-diagnosis-and-prognostication/353717.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How have genomic and proteomic biomarker discoveries changed cancer diagnosis and prognosis?","Question",{"text":113,"@type":114},"They have improved diagnosis, risk stratification, and prognosis, and they support better treatment selection by enabling more precise, personalized approaches.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which technologies and approaches are driving modern biomarker discovery?",{"text":118,"@type":114},"Next-generation sequencing, mass spectrometry, and advanced bioinformatics enable multi-omics strategies for biomarker identification and validation.",{"name":120,"@type":111,"acceptedAnswer":121},"What role do liquid biopsies and artificial intelligence play in this field?",{"text":122,"@type":114},"Liquid biopsies and AI are emphasized as tools that accelerate biomarker identification and validation, supporting integrative multi-omics analytics for clinical translation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353717,1790334537,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Rajput et al. World Journal of Surgical Oncology (2026) 24:87  \n[https://doi.org/10.1186/s12957-025-04185-3](https://doi.org/10.1186/s12957-025-04185-3)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nNew genomic and proteomic biomarker  discovery in cancer: revolutionizing diagnosis and prognostication  \nMonika Rajput1,2, Manoj Pandey1,2,3 and Ruhi Dixit3*  \nAbstract  \nCancer remains a major global health challenge, with substantial morbidity and mortality worldwide. Advancesin genomic and proteomic biomarker discovery have transformed cancer diagnosis, prognosis, and treatment selection. The evolution from early serological markers such as carcinoembryonic antigen (CEA) and prostatespecific antigen (PSA) to modern multi-omics approaches enabled by next-generation sequencing (NGS), mass spectrometry (MS), and advanced bioinformatics has revolutionized personalized medicine and targeted therapy, leading to improved outcomes. This review highlights the historical evolution of cancer biomarkers and the current landscape of genomic, proteomic, and proteogenomic biomarkers. We emphasize the role of liquid biopsies, artificial intelligence (AI), and integrative multi-omics analytics in accelerating biomarker identification and validation. We also discuss the differential pace of clinical adoption in high-income versus low-and middle-income countries (LMICs), and outline ongoing challenges including tumor heterogeneity, standardization, cost, and regulatory barriers. Despite these limitations, recent innovations in multi-omics technologies and AI-driven analysis promise to further advance precision oncology and enable more equitable, personalized cancer care worldwide. Keywords Cancer, Genomic, Proteomic, Biomarkers, Bioinformatics, Multi-omics, Artificial intelligence  \nBackground  \nCancer continues to be a major global health burden, with approximately 20 million new cases and 9.7 million deaths reported worldwide in 2022, according to the GLOBOCAN 2022 publication [1]. The intricate heterogeneity of cancer has long challenged early detection, accurate diagnosis, and effective treatment. Over the  \n*Correspondence:  \nRuhi Dixit  \n[ruhi.dixit3@bhu.ac.in](ruhi.dixit3@bhu.ac.in)  \n1DHR-ICMR Advanced Molecular Oncology Diagnostic Services (DIAMOnDS), Institute of Medical Sciences, Banaras Hindu University, Varanasi 221,005, India  \n2Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221,005, India  \n3Health Technology Assessment India (HTAIn) resource centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221,005, India  \npast few decades, the rise of genomic and proteomic biomarker discovery, driven by advancements in bioinformatics and open-access data repositories, has reshaped the oncology landscape, enabling precision medicine.  \nThis review on “New Genomic and Proteomic Biomarker Discovery in Cancer” traces the historical evolution, development, and validation of genomic and proteomic biomarkers, emphasizing how scientific progress, technological innovations, bioinformatics, and open-access data have driven their identification and how these biomarkers have transformed cancer diagnosis and prognostication, improving patient outcomes. We further examine how these biomarkers are transforming cancer diagnosis and prognostication, and explore practical considerations for implementing such technologies  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or ","cbCaik5ytxtoFZea","https://ap.wps.com/l/cbCaik5ytxtoFZea","pdf",2154816,15,"English","# Abstract\n# Background\n# Added value of the study\n# Historical evolution of cancer biomarkers","[{\"question\":\"How have genomic and proteomic biomarker discoveries changed cancer diagnosis and prognosis?\",\"answer\":\"They have improved diagnosis, risk stratification, and prognosis, and they support better treatment selection by enabling more precise, personalized approaches.\"},{\"question\":\"Which technologies and approaches are driving modern biomarker discovery?\",\"answer\":\"Next-generation sequencing, mass spectrometry, and advanced bioinformatics enable multi-omics strategies for biomarker identification and validation.\"},{\"question\":\"What role do liquid biopsies and artificial intelligence play in this field?\",\"answer\":\"Liquid biopsies and AI are emphasized as tools that accelerate biomarker identification and validation, supporting integrative multi-omics analytics for clinical translation.\"}]","New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication | PDF",1790106933,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7951b47fdefe5a356c39f8ab064bd1c2.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50b765d91004d285ab06bb30c1c11a3c.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f7b8dec15a338bbaf5d11622132a31f.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9222f442e58f209de4656d56b6b40192.webp",980,1306]